Transcatheter Arterial Chemo-Embolization (TACE) vs. Sorafenib in Patients with Hepatocellular Carcinoma Refractory to TACE: A Randomized Phase II Trial - Transcatheter Arterial Chemo-Embolization (TACE) vs. Sorafenib in Patients with Hepatocellular Carcinoma Refractory to TACE: A Randomized Phase II Trial

The University of Tokyo, Department of Gastroenterology0 个研究点目标入组 240 人开始时间: 2013年1月31日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Patients who received sorafenib or molecular target drug in the past 3 months. 2.Patients receiving the treatment (other than study drug or procedure) for HCC. 3.Patients who have an allergic history to the study drug. 4.Patients during pregnancy, breast-feeding, or at risk of becoming pregnant. 5.Patients without indication for TACE. 6.Patients on dialysis. 7.Patients with poorly-controlled hypertension (systolic blood pressure > 170mmHg on medication) 8.Patients with esophageal varices who have a risk for bleeding, or the patients with the history of gastrointestinal hemorrhage within a month. 9.Patients with current or past history of hepatic encephalopathy. 10.Patients with a history of liver transplantation. 11.Patients receiving drugs that affect CYP3A4 or UGT1A9 (e.g.Rifampicin). 12.Patients with other primary malignancies. 13.Patients infected with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). 14.Patients considered inappropriate by the study investigator.

发起方

The University of Tokyo, Department of Gastroenterology